Zambia / South Africa / Kenya / France / Uganda / Tanzania / United Kingdom / / /
Facility
Zambia University Teaching Hospital / Medical Research Council Uganda Virus Research Institute / The Johns Hopkins University / University Teaching Hospital / National Institute / Uganda Medical Research Council Uganda Virus Research Institute / Institute Gustave-Roussy / University of Witwatersrand / Mulago Hospital / /
IndustryTerm
HIV prevention / trial protocol / higher concentration product / food / potential vaginal microbicide product / study site / investigational product / strength product / /
MedicalCondition
HIV / HIV infection / sexually transmitted infections / infection / /
MedicalTreatment
counselling / /
Organization
The Johns Hopkins University / Independent Data Monitoring Committee / National Institute for Medical Research / South African Medical Research Council / Mulago Hospital / Medical Research Council Uganda Virus Research Institute / Department of Obstetrics and Gynaecology / World Health Organisation / Reproductive Health and HIV Research Unit / Department for International Development / Alliance for Microbicides Development / MDP Trial Steering Committee / Service of Biostatistics and Epidemiology / University of Witwatersrand / Johannesburg / Africa Centre for Health and Population Studies / UK Medical Research Council / Africa Centre / African Medical and Research Foundation / University Teaching Hospital / Medicines and Healthcare products Regulatory Agency / JHPIEGO / /
Person
Florence Mirembe / Isaac Malonza / Catherine Hill / Alasdair Breckenridge / Helen Rees / Anatoli Kamali / Claire Moffat / Maureen Chisembele / / /
Position
Principal Investigator / Head / Chairman / Deputy Country Director / Professor / Head of Obstetrics and Gynaecology / /
MDP_Q&A_14Feb08_v1.2_FINAL Q&A Microbicides Development Programme (MDP) update: MDP301 Phase III trial continues but one arm closes 1. What is the MDP301 trial?